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France, 2Laboratoire de Génétique des Virus Oncogènes, URA 1301 CNRS, Institut 
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Ko prostate cancer treatment has proven to be efficient as soon as the 
tumour become invasive. It is therefore of some importance to design a a 
new therapeutical approach using cellular and molecular biology tools. A 
major breakthrough may come from the development of a tissue specific 
transfer strategy of «suicide» genes as a gene therapy. This approach may 
allow the treatment of primary cancer and distant metastasis. Indeed, the 
specific targeting of prostate cells should render métastasés accessible to 
therapy for the first time in prostate cancer.
Three stages arc involved in development of human gene therapy, (i) the 
transduction by viral vectors or transfection by DNA-mediated systems of 
appropriate target cells, (ii) enhancement of prostate-specific gene 
expression, and (iii) the feasibility assessment of different effector genes to 
direct «suicide» or proliferation control of the targeted prostate cancer 
cells. To test these alternatives, we have standardised in vitro and in vivo 
models: human prostatic epithelial and fibroblatic cells lines (Int. J; Oncol, 
6: 333-343, 1995), human-rodent xenografts and non human primates.
By using recombinant adenovirus expressing the gene reporter ß- 
galactosidase (rAd-RSV- ß-gal) and the suicide gene thymidine kinase 
(rAd-HSV-tk) we have tested in vitro the efficiency of transfection as well 
as the toxicity of the tk/ganciclovir treatment. In primary cultures of 
human prostate cancer epithelial and fibroblastic cells, we observed a 
transduction of the reporter gene in 100% of the epithelial cells with 100 
virus particles per cell, while the fibroblastic cells dispayed scarse staining. 
This epithelial selectivity to rAd was further confirmed on the immortalised 
human prostatic cells lines PNT2 and PNT1A, known to be extremly 
insensitive to transfection. Confirmation of this selectivity has been carried 
out in human prostate cancer xenograft on nude mice while tk toxicity was 
assayed in vitro and in vivo.
As a result, we expect to improve the efficiency of the cellular and 
molecular targeting to prostate cancer. By providing a new approach to 
treat prostate cancer, it should assist in a significant improvement for both 
the patient and the social budget
GENERATION OF ANTI-IDIOTYPE MONOCLONAL ANTIBODIES RELATED TO 
PSA. *Uemura H, Kitagawa H, Ozono S, Hirao Y, and Okajima E.
Dept. Urology, Nara Med. Univ. Nara, Japan.
As a consequence of the idiotype network theory it has been suggested that 
internal image anti-idiotype antibodies must be able to substitute for the nominal 
antigen. Therefore, the development of monoclonal anti-idiotype antibodies (Ab2) 
bearing the internal image of a tumor-asscciated antigen (TAA) is of great interest.
Prostate specific antigen (PSA) has proven to be useful as an indicator for 
disease progression and response to treatment in prostate cancer (PCa). Since 
tumors derived from other organs do not show PSA expression, PSA has been 
successfully used as a maker in PCa patients. However because of PSA production 
from normal prostate cells, a number of falso positive has been obserbed in patients 
with BPH. «Vioreover. recent investigations revealed that several molecular forms,
i.e., free-PSA, complexed-PSA, exist in the serum and the seminal fluid. However 
biological activities of these have not been clarified, i.e., the regulation of PSA 
activity. These characteristics make this antigen a good candidate for anti-idiotype 
approach.
For generation of Ab2, anti-PSA mouse MAb lgG1-kappa(Ab1) was cross-linked 
to Keyhole Limpet Hemocyanln and used as immunogen. BALB/c mice were 
immunized with Ab1-KlH , which specifically reacts with PSA and their splénocytes 
were fused with SP2/Û mouse myeloma cells. In 3 fusions, 6 anti-idiotype antibodies 
specifically reacting with anti-PSA MAb were isolated from more than 3000 
hybridomas. Of these, two blocked binding of Ab1 to PSA, indicating that specificity 
for the anti-PSA MAb binding pocket and not for the CH2 (outside pocket) of lgG1. 
Furthermore, these Ab2 were tested in Western blots to determine the reactivity 
with reduced and non-reduced anti-PSA MAb IgG. All Ab2 showed clear binding tc 
anti-PSA MAb in non-reluced gels, wheares no reactivity was observed in reduce j 
gels, indicating that Ab2 recognize a conformational epitope compromized of heav y 
and light chain, and not a structual epitope outside anti-PSA MAb binding site. V le 
have also initiated the functional characterization of these Ab2, i.e., whether tl ey 
are able to induce antibodies capable to compete with the parental anti-PSA M vb. 
For the generation of anti-anti-idiotype antibodies (Ab3) resembling Ab1 (AM'), 
NZW rabbits were immunized with purified Ab2, Sera from rabbits immunized with 
Ab2 showed reactivity with PSA but not with antigen-negative control cell lysUes, 
indicating Ab1' induction,
In summary, we have isolated 2 anti-idiotype MAbs that appear to bear the 
internal image of PSA. Such Ab2 can be tested for PSA enzymatic activities and 
therapeutic potential. We are currently performing cross-blocking RIA to determine 
whether these Ab2 recognize different epitopes in anti-PSA MAb binding pocket.
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POLYAMINE METABOLISM AND PROGRAMMED CELL DEATH
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The standard therapy used for the treatment of metastatic prostatic cancer, 
androgen ablation, fails to induce programmed cell death in androgen- 
independent prostatic cancer cells. However, in vitro, androgen-independent 
cells can be triggered {by calcium lonophores} to undergo apoptosis, i.e. the 
pathway needed for this programmed cell death is retained. Recent evidence 
indicates that polyamines are associated with programmed cell death. Based 
on these considerations we studied, using an in vitro system, whether 
polyamine biosynthesis (ODC activity) and intracellular levels of polyamines 
are changed during calcium-ionophore induced apoptosis of androgen 
independent prostatic cancer cells. In addition, we Investigated whether 
compounds known to Interfere with polyamine metabolism (DFMO, BENSpm, 
MDL72527) effected the process of programmed cell death. Studies were 
performed with the highly metastatic, androgen-independent AT-3 tumour 
subline. To detect apoptotic cells the ISNT {in situ nick translation) technique 
was used to visualize fragmented DNA in cultured AT-3 cells . In AT-3 cells 
treated with 10 juM Ionomycin a pronounced increase of cellular DNA 
fragmentation and fragmented cells (apoptotic bodies) were observed. ODC 
activity was augmented under these conditions. Putrescine levels increased 
whilst spermidine and spermine levels decreased. Subsequently, we 
Investigated whether apoptosis can be initiated or prevented by manipulating 
polyamine metabolism. Cells were treated with DFMO, BENSpm or MDL72527 
in combination with 10 //m Ionomycin to induce apoptosis. These studies 
showed that if putrescine biosynthesis is blocked (by DFMO) and/or 
polyamines are depleted (by BENSpm) cells cease to proliferate but fall to 
undergo apoptosis after treatment with ionomycin. These results suggest a 
role for ODC activity and/or polyamines In the Induction and/or progression of 
apoptosis in prostatic cancer cells. Inhibition of polyamine oxidase by 
MDL72527 did not Interfere with apoptosis which suggest that oxidation 
products produced from polyamine oxidation are not involved in apoptosis of 
prostatic cancer cells.
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PROSTATE TUMOR GROWTH ENHANCEMENT AND MODULATION OF 
NATURAL KILLER CELL ACTIVITY BY TRANSFORMING GROWTH FACTOR 
BETA 1 (TGF ß1). Hans E, Contractor and Evelyn R. Barrack, Baltimore, MD. 
(Presented by Dr. Contractor)
Engineered TGF-ß1 overexpression in prostate cancer cells (Dunning subline 
R3327 MATLyLu) causes significantly larger tumors than parental MATlyLu (MIL) 
tumors. Importantly, TGF-ß1 overproducing (TGF-OP) and control tumors both have 
the same doubling time. Flow cytometry revealed that both tumor types also had the 
same percentage of cells in S-phase. Therefore TGF-ß1 overexpression affects tumor 
size without affecting the rate of proliferation or growth. However, in T-cell deficient 
animals like nude mice or nude rats no size differences between TGF-OP and MLL 
tumors after inoculation of 5x105 tumorcells was seen, from which we assumed that an 
inhibition of T-lymphocytes in TGF-OP tumors is responsible for larger tumore The 
same effect of eliminating size differences between TGF-OP and MLL tumors was 
observed in Copenhagen rats which Natural killer (NK)-cell activity had been either 
stimulated by daily intra peritonea I (i.p.) injection of 1.2 mg Poly l:C, a potent stimulator 
of interferon production, or inhibted by injection of 200pl ASGMrantibody (Wako, 
Richmond VA) i.p. 3 days before cell inoculation and at additional intervals (days 
2,6,10,14,17) afterwards, implying a role of NK-cells in prostate tumor growth 
modulation by TGF-ß1 (Contractor / Breul / Barrack, J.Urol. 151:366A, 1994). These 
data represented a paradox because both T- and NK-cells seemed responsible for 
tumor growth enhancement in TGF-OP tumors. Assuming an influence of inoculated 
cell number on prostate tumor growth in nude mice, tumorcell inocula with increasing 
numbers of TGF-OP or MLL tumor cells were examined for their ability to form tumors. 
Interestingly, after Inoculation of 2x106, 1x10® or 5x10s tumorcells no difference in tumor 
volume was observed between MLL and TGF-OP tumors (2x10ë_: 6.99±0.93 ver. 
7.32±0.46; 1x10s : 5.91+1.07 ygr. 7.21+0.83; 5x10s- : 4.84+0.81 m  7.28+0.85 ) 
(mean+SE). In contrast a significant difference between TGF-OP and MLL tumor 
volumes in nude mice was observed after inoculation of 5x104 tumor cells (5x104 :
1.89±0.30 yêt. 3.42±0.35 (p<0.005)). The growth promoting effect of TGF-ß1 is also 
apparent in nude mice but only in low number cell inocula. Therefore effects of TGF-ß1 
on T-lymphocytes are not responsible for the observed growth promotion in TGF-OP 
tumors. Thus, it appears that in ratsTGF ß1 overexpression may enhance tumor 
growth at least in part by inhibiting NK-cell function and thus enabling more tumor cells 
to survive immune surveillance and produce larger tumors. (Supported by CA 16924 
and DFG Co 183/1).
